VivoSim Labs, Inc.: Strategic Divestiture and Transition to Non-Animal NAM Platform in San Diego Implodes as $10.8 Million Operating Cash Burn Signals Going Concern Deficit
Date : 2026-07-17
Reading : 162
HDIN Executive Takeaways
1. VivoSim Labs, Inc. has executed a complete pivot to a B2B non-animal New Approach Methodologies (NAM) services model at its San Diego facility, capitalizing on the FDA's April 10, 2025 mandate to reduce animal testing.
2. Financial survival is highly constrained, with a $10.83 million operating cash burn leaving a calculated cash runway of 5.57 months on its $5.02 million unencumbered cash balance.
3. Catastrophic dilution risks persist via 7.32 million reserved shares and a toxic price-protection warrant mechanism that could mandate the issuance of 720.7 million new shares, far exceeding the company's 196.5 million authorized unissued share capacity.
Figure VivoSim Labs FY 2026: The Strategic Pivot to NAMs Ecosystem
Segmental Realities, Toxic Dilution, and Margin Compression
VivoSim Labs, Inc. is undergoing a complete corporate restructuring, abandoning its clinical-stage therapeutic pipeline to operate strictly as a preclinical-stage services provider. Following the strategic shutdown of its physical cell-production division, Mosaic Cell Sciences, in the third quarter of FY 2025, the company generated $0 in product or service revenue for FY 2026.
Total revenue for FY 2026 was $131,000, representing a 100% concentration in a single passive line item: sales-based royalty revenue generated through an intellectual property licensing agreement with BICO Group AB [STO: BICO]. Cost of Goods Sold (COGS) for the fiscal year was $0, yielding a gross margin of 100%, reflecting the shift away from physical manufacturing to royalty and service models.
The company’s R&D spend of $4.19 million was expensed entirely as incurred under a strict non-capitalization policy. This spend includes $3.93 million in direct research and development, $0.06 million in non-cash stock-based compensation, and $0.20 million in depreciation and amortization. Conversely, SG&A expenses of $7.43 million (63.9% of OPEX) reflect an administrative structure that outweighs direct scientific development.
Capital Structure and the Dilution Trap
The capital architecture is highly leveraged and dilutive. Against a thin baseline of 2.89 million actively outstanding common shares, the company has 7.32 million shares reserved for future issuance, consisting of:
* Warrants: 6.96 million
* Stock Options: 0.26 million
* Restricted Stock Units (RSUs): 0.075 million
In March 2026, VivoSim Labs, Inc. completed a public offering yielding $2.4 million in net proceeds through the issuance of 286,557 common shares, 2.34 million pre-funded warrants, and 3.95 million common warrants. It also utilized its at-the-market (ATM) facility with JonesTrading to sell 701,729 shares for $1.8 million in net proceeds during FY 2026.
The 2026 Common Warrants contain a toxic, cashless price-protection mechanism based on a Black-Scholes valuation divided by the lower of the two closing bid prices prior to exercise, subject to a $0.01 floor. If the stock price triggers this $0.01 floor, the company is contractually obligated to issue 720.7 million new shares. Because VivoSim Labs, Inc. only has 196.5 million authorized unissued shares available, executing this clause would violate its corporate charter, introducing severe legal and capital compliance crises.
Infrastructure Layout, Academic Transitions, and the Viscient Related-Party Network
VivoSim Labs, Inc. has consolidated its physical footprint to a single facility encompassing approximately 10,943 square feet of permanently leased laboratory and office space at 11555 Sorrento Valley Road, San Diego, California. The lease, which commenced on December 17, 2021, features a monthly base rent of approximately $40,800 subject to a 3% annual escalator. The lease expires in early calendar year 2027, concentrating the remaining future undiscounted lease obligations of $459,000 entirely in FY 2027, leaving $0 in lease commitments for years 2 through 5.
Following the shutdown of Mosaic Cell Sciences, the company has zero vertical integration for human cell manufacturing, rendering its 3D bioprinting and NAM services 100% dependent on third-party biological suppliers.
Intellectual Property and Academic De-Risking
The company holds a global portfolio of over 160 patents and pending applications, including 39 solely owned or exclusively licensed U.S. patents and over 50 international patents.
* Core NovoGen Bioprinter Hardware: Protected by 12 U.S. and 15 foreign patents with remaining terms of 7 to 9 years.
* NAMkind Liver Tissue: Protected by 4 U.S. and 4 international patents with remaining terms of 8 to 10 years.
To eliminate ongoing financial outlays, the company has aggressively restructured its academic licensing agreements:
* University of Missouri / MUSC (Forgacs IP): In December 2022, the company extinguished its 1% to 3% sales-based royalty by executing a single upfront payment of $50,000, converting the contract into a fully paid-up license through its June 2028 expiration.
* Clemson University (CURF IP): This license, which previously carried a $40,000 annual minimum royalty, officially expired in May 2024. VivoSim avoided paying royalties at expiration by offsetting historic legal defense expenses.
Governance Risks and Related-Party Capital Bleed
A critical governance concern is the asymmetric relationship with Viscient Biosciences, a private company founded and led by VivoSim’s Executive Chairman, Keith Murphy (who also serves as Viscient’s CEO). Three of VivoSim's "independent" directors (Adam Stern, Douglas Jay Cohen, and David Gobel) hold personal financial stakes in Viscient via convertible promissory notes.
Under a December 2020 Intercompany Agreement to share facilities and employees, VivoSim's cash outflows to Viscient for "R&D consulting expenses" surged by 411% to $604,000 in FY 2026, up from $118,000 in FY 2025. In contrast, Viscient paid VivoSim a mere $5,000 for histology services. Viscient also holds a paid-up, perpetual, non-exclusive license to use VivoSim's core bioprinting patents.
The executive team is highly outsourced:
* Executive Chairman (PEO): Keith Murphy's services are retained via his firm, Multi Dimensional Bio Insight LLC (MDBI), which received $800,174 in consulting fees in FY 2026 (up from $726,674 in FY 2025) plus a $73,500 cash bonus.
* CFO: Norman Staskey is outsourced via Danforth Advisors LLC, which was paid $119,475 in FY 2026. Mr. Staskey holds zero equity.
* New Hires: CCO Tony Lialin (hired August 2025) and CSO Amar Sethi (hired November 2025) receive base salaries of $360,000. In FY 2026, they received cash bonuses of $88,615 and $47,077, respectively, and hold 40,000 and 53,500 options.
* Insider Alignment: Total executive and director insider ownership stands at a negligible 2.1% (65,179 shares). Esousa Group Holdings LLC (Michael Wachs) holds 322,723 shares, capped at 9.99% due to a blocker provision, but maintains massive derivative overhang via 1,708,856 pre-funded warrants and 3,947,369 common warrants.
HDIN Institutional Verdict
VivoSim Labs, Inc. presents an asymmetric risk-reward profile heavily weighted toward down-side distress. While its NAMkind Liver platform demonstrates excellent clinical validation—specifically an 87.5% sensitivity rate and 100% specificity rate in predicting drug-induced liver injury (presented at Digestive Disease Week in May 2025)—its commercialization is in an embryonic phase. Generating $0 in organic service revenue in FY 2026, the business is currently sustained by a passive, legacy $131,000 royalty from BICO Group AB and structured divestiture cash from Eli Lilly and Company \[NYSE: LLY\], which paid a $5.0 million development milestone in July 2026 following the March 2025 divestiture of the FXR314 therapeutic asset.
The company’s survival is threatened by immediate financial and regulatory headwinds. Rosenberg Rich Baker Berman, P.A. (RRBB) has issued a formal "Going Concern" explanatory qualification. VivoSim Labs, Inc. is in breach of Nasdaq listing standards with negative stockholders' equity of $1.1 million (against the $2.5 million minimum) and a sub-$1.00 share price, placing it at risk of imminent delisting.
Furthermore, the company is defending a breach-of-contract lawsuit filed by H.C. Wainwright in the Supreme Court of New York, leading to a recognized $0.6 million loss contingency accrual ($400,000 in accrued expenses, $200,000 in equity-settled liabilities).
Given the combination of a high cash burn rate of $10.83 million, a severe authorized share deficit, and non-arm's-length capital bleed to Viscient Biosciences, institutional investors must prepare for imminent corporate restructuring, dilutive recapitalization, or OTC relegation.
Presentation Download & Video Access:
Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at [http://www.hdinresearch.com](http://www.hdinresearch.com).
2026 AI Transparency Footer:
"This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards."
1. VivoSim Labs, Inc. has executed a complete pivot to a B2B non-animal New Approach Methodologies (NAM) services model at its San Diego facility, capitalizing on the FDA's April 10, 2025 mandate to reduce animal testing.
2. Financial survival is highly constrained, with a $10.83 million operating cash burn leaving a calculated cash runway of 5.57 months on its $5.02 million unencumbered cash balance.
3. Catastrophic dilution risks persist via 7.32 million reserved shares and a toxic price-protection warrant mechanism that could mandate the issuance of 720.7 million new shares, far exceeding the company's 196.5 million authorized unissued share capacity.
Figure VivoSim Labs FY 2026: The Strategic Pivot to NAMs Ecosystem
Segmental Realities, Toxic Dilution, and Margin CompressionVivoSim Labs, Inc. is undergoing a complete corporate restructuring, abandoning its clinical-stage therapeutic pipeline to operate strictly as a preclinical-stage services provider. Following the strategic shutdown of its physical cell-production division, Mosaic Cell Sciences, in the third quarter of FY 2025, the company generated $0 in product or service revenue for FY 2026.
Total revenue for FY 2026 was $131,000, representing a 100% concentration in a single passive line item: sales-based royalty revenue generated through an intellectual property licensing agreement with BICO Group AB [STO: BICO]. Cost of Goods Sold (COGS) for the fiscal year was $0, yielding a gross margin of 100%, reflecting the shift away from physical manufacturing to royalty and service models.
Table Financial & Operating Metrics (FY2026)
| Financial Metric (FY2026) | Value (USD / Percentage) |
|---|---|
| Total Revenue | $131,000 |
| Gross Margin | 100.0% (COGS: $0.00) |
| Research & Development (R&D) Expenses | $4.19M |
| Selling, General & Administrative (SG&A) Expenses | $7.43M |
| Total Operating Expenses (OPEX) | $11.62M |
| R&D as % of Total OPEX | 36.1% |
| Cash & Cash Equivalents | $5.02M |
| Restricted Cash (Lease Collateral) | $0.14M |
| Net Cash Used in Operating Activities | ($10.83M) |
| Implied Monthly Cash Burn | ~$0.90M |
| Calculated Cash Runway | 5.57 Months |
| Common Stock Outstanding | 2.89M Shares |
| Shares Reserved for Future Issuance | 7.32M Shares |
The company’s R&D spend of $4.19 million was expensed entirely as incurred under a strict non-capitalization policy. This spend includes $3.93 million in direct research and development, $0.06 million in non-cash stock-based compensation, and $0.20 million in depreciation and amortization. Conversely, SG&A expenses of $7.43 million (63.9% of OPEX) reflect an administrative structure that outweighs direct scientific development.
Capital Structure and the Dilution Trap
The capital architecture is highly leveraged and dilutive. Against a thin baseline of 2.89 million actively outstanding common shares, the company has 7.32 million shares reserved for future issuance, consisting of:
* Warrants: 6.96 million
* Stock Options: 0.26 million
* Restricted Stock Units (RSUs): 0.075 million
In March 2026, VivoSim Labs, Inc. completed a public offering yielding $2.4 million in net proceeds through the issuance of 286,557 common shares, 2.34 million pre-funded warrants, and 3.95 million common warrants. It also utilized its at-the-market (ATM) facility with JonesTrading to sell 701,729 shares for $1.8 million in net proceeds during FY 2026.
The 2026 Common Warrants contain a toxic, cashless price-protection mechanism based on a Black-Scholes valuation divided by the lower of the two closing bid prices prior to exercise, subject to a $0.01 floor. If the stock price triggers this $0.01 floor, the company is contractually obligated to issue 720.7 million new shares. Because VivoSim Labs, Inc. only has 196.5 million authorized unissued shares available, executing this clause would violate its corporate charter, introducing severe legal and capital compliance crises.
Infrastructure Layout, Academic Transitions, and the Viscient Related-Party Network
VivoSim Labs, Inc. has consolidated its physical footprint to a single facility encompassing approximately 10,943 square feet of permanently leased laboratory and office space at 11555 Sorrento Valley Road, San Diego, California. The lease, which commenced on December 17, 2021, features a monthly base rent of approximately $40,800 subject to a 3% annual escalator. The lease expires in early calendar year 2027, concentrating the remaining future undiscounted lease obligations of $459,000 entirely in FY 2027, leaving $0 in lease commitments for years 2 through 5.
Following the shutdown of Mosaic Cell Sciences, the company has zero vertical integration for human cell manufacturing, rendering its 3D bioprinting and NAM services 100% dependent on third-party biological suppliers.
Intellectual Property and Academic De-Risking
The company holds a global portfolio of over 160 patents and pending applications, including 39 solely owned or exclusively licensed U.S. patents and over 50 international patents.
* Core NovoGen Bioprinter Hardware: Protected by 12 U.S. and 15 foreign patents with remaining terms of 7 to 9 years.
* NAMkind Liver Tissue: Protected by 4 U.S. and 4 international patents with remaining terms of 8 to 10 years.
To eliminate ongoing financial outlays, the company has aggressively restructured its academic licensing agreements:
* University of Missouri / MUSC (Forgacs IP): In December 2022, the company extinguished its 1% to 3% sales-based royalty by executing a single upfront payment of $50,000, converting the contract into a fully paid-up license through its June 2028 expiration.
* Clemson University (CURF IP): This license, which previously carried a $40,000 annual minimum royalty, officially expired in May 2024. VivoSim avoided paying royalties at expiration by offsetting historic legal defense expenses.
Governance Risks and Related-Party Capital Bleed
A critical governance concern is the asymmetric relationship with Viscient Biosciences, a private company founded and led by VivoSim’s Executive Chairman, Keith Murphy (who also serves as Viscient’s CEO). Three of VivoSim's "independent" directors (Adam Stern, Douglas Jay Cohen, and David Gobel) hold personal financial stakes in Viscient via convertible promissory notes.
Under a December 2020 Intercompany Agreement to share facilities and employees, VivoSim's cash outflows to Viscient for "R&D consulting expenses" surged by 411% to $604,000 in FY 2026, up from $118,000 in FY 2025. In contrast, Viscient paid VivoSim a mere $5,000 for histology services. Viscient also holds a paid-up, perpetual, non-exclusive license to use VivoSim's core bioprinting patents.
The executive team is highly outsourced:
* Executive Chairman (PEO): Keith Murphy's services are retained via his firm, Multi Dimensional Bio Insight LLC (MDBI), which received $800,174 in consulting fees in FY 2026 (up from $726,674 in FY 2025) plus a $73,500 cash bonus.
* CFO: Norman Staskey is outsourced via Danforth Advisors LLC, which was paid $119,475 in FY 2026. Mr. Staskey holds zero equity.
* New Hires: CCO Tony Lialin (hired August 2025) and CSO Amar Sethi (hired November 2025) receive base salaries of $360,000. In FY 2026, they received cash bonuses of $88,615 and $47,077, respectively, and hold 40,000 and 53,500 options.
* Insider Alignment: Total executive and director insider ownership stands at a negligible 2.1% (65,179 shares). Esousa Group Holdings LLC (Michael Wachs) holds 322,723 shares, capped at 9.99% due to a blocker provision, but maintains massive derivative overhang via 1,708,856 pre-funded warrants and 3,947,369 common warrants.
HDIN Institutional Verdict
VivoSim Labs, Inc. presents an asymmetric risk-reward profile heavily weighted toward down-side distress. While its NAMkind Liver platform demonstrates excellent clinical validation—specifically an 87.5% sensitivity rate and 100% specificity rate in predicting drug-induced liver injury (presented at Digestive Disease Week in May 2025)—its commercialization is in an embryonic phase. Generating $0 in organic service revenue in FY 2026, the business is currently sustained by a passive, legacy $131,000 royalty from BICO Group AB and structured divestiture cash from Eli Lilly and Company \[NYSE: LLY\], which paid a $5.0 million development milestone in July 2026 following the March 2025 divestiture of the FXR314 therapeutic asset.
The company’s survival is threatened by immediate financial and regulatory headwinds. Rosenberg Rich Baker Berman, P.A. (RRBB) has issued a formal "Going Concern" explanatory qualification. VivoSim Labs, Inc. is in breach of Nasdaq listing standards with negative stockholders' equity of $1.1 million (against the $2.5 million minimum) and a sub-$1.00 share price, placing it at risk of imminent delisting.
Furthermore, the company is defending a breach-of-contract lawsuit filed by H.C. Wainwright in the Supreme Court of New York, leading to a recognized $0.6 million loss contingency accrual ($400,000 in accrued expenses, $200,000 in equity-settled liabilities).
Given the combination of a high cash burn rate of $10.83 million, a severe authorized share deficit, and non-arm's-length capital bleed to Viscient Biosciences, institutional investors must prepare for imminent corporate restructuring, dilutive recapitalization, or OTC relegation.
Presentation Download & Video Access:
Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at [http://www.hdinresearch.com](http://www.hdinresearch.com).
2026 AI Transparency Footer:
"This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards."